Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth.
The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.
As 2025 winds down, the biotechnology sector is heating up, signaling a rare window of opportunity for investors. After a period of uneven performance, the industry is regaining momentum, with the global biotech market projected to grow from $1.74 trillion in 2025 to more than $5 trillion by 2034, reflecting a robust annual growth rate of 12.5 percent.
Since April 2025, Eli Lilly has been in a holding pattern, posting a small loss of 2.2% while floating around $811. The stock also fell short of the S&P 500’s 24.7% gain during that period.
The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift towards personalized medicine. Artificial intelligence (AI) stands at the forefront of this revolution, offering unprecedented capabilities to overcome long-standing challenges and accelerate the delivery of tailored, effective treatments. [...]
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase (BTK) degrader,
Copenhagen, Denmark – October 22, 2025 – Novo Nordisk (NYSE: NVO) shares experienced a notable decline this week following the announcement of a comprehensive board overhaul, a decisive move orchestrated by its top investor, the non-profit Novo Nordisk Foundation. The shake-up, which will see seven independent board members, including the chairman, step
Looking for high-upside stocks in 2025? AMD, UBER, and LLY each offer over 30% EPS growth potential and analyst-backed price targets with double-digit gains.
